Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study

[1]  T. H. van der Kwast,et al.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. , 2007, European urology.

[2]  A. Renshaw,et al.  Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. , 2006, The Journal of urology.

[3]  A. Partin,et al.  Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. , 2006, The Journal of urology.

[4]  K. Mitsumori,et al.  Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population. , 2006, The Journal of urology.

[5]  W. Catalona,et al.  Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. , 2005, Urology.

[6]  W. Catalona,et al.  Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. , 2005, Urology.

[7]  David Robinson,et al.  Survival in prostate carcinoma—Outcomes from a prospective, population‐based cohort of 8887 men with up to 15 years of follow‐up , 2005, Cancer.

[8]  P. Kantoff,et al.  Racial differences in screening for prostate cancer in the elderly. , 2004, Archives of internal medicine.

[9]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[10]  M. Terris,et al.  Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate‐specific antigen levels , 2004, Cancer.

[11]  B. G. Blijenberg,et al.  Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. , 2004, The Journal of urology.

[12]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[13]  G. Bartsch,et al.  Early detection of prostate cancer with low PSA cut‐off values leads to significant stage migration in radical prostatectomy specimens , 2003, The Prostate.

[14]  P. Humphrey,et al.  Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.

[15]  Alan W Partin,et al.  Prostate-specific antigen as a marker of disease activity in prostate cancer. , 2002, Oncology.

[16]  A. Renshaw,et al.  Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less. , 2002, The Journal of urology.

[17]  D. Grignon,et al.  Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease‐free survival after radical prostatectomy , 2001, The Prostate.

[18]  D. Johnston,et al.  The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. , 2001, The Journal of urology.

[19]  J. Moul,et al.  Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. , 2000, Urology.

[20]  Z. Zhang,et al.  Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. , 2000, Urology.

[21]  H. D. de Koning,et al.  Prostate cancer detection at low prostate specific antigen. , 2000, The Journal of urology.

[22]  W. Demark-Wahnefried,et al.  Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. , 1999, Urology.

[23]  J. Hugosson,et al.  Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. , 1998, The Journal of urology.

[24]  Ø. Kravdal,et al.  The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts. , 1997, Preventive medicine.

[25]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[26]  D. Chan,et al.  Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. , 1997, JAMA.

[27]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[28]  T. Stamey,et al.  Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less. , 1996, The Journal of urology.

[29]  A. Pollack,et al.  Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. , 1995, Urology.

[30]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[31]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[32]  W. S. Lazarus-Barlow,et al.  THE NATURAL DURATION OF CANCER , 1924, British medical journal.

[33]  A. Lu,et al.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.

[34]  A. Partin,et al.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.

[35]  E. Leifer,et al.  Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. , 1999, Urology.

[36]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.